Drug Approval | May 25, 2026
EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
The decision marks a key step in the centralized EU review process
The decision marks a key step in the centralized EU review process
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
